Patients with advanced and nonadvanced adenomas are at an increased risk for CRC, but only those with advanced adenomas had ...

Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal Medicine at Texas Tech University Health Sciences Center (TTUHSC) and director of the ...

Hepatocellular carcinoma continues to pose a diagnostic challenge, particularly in the setting of underlying pathomorphological changes in the liver due to cirrhosis, steatosis, or steatohepatitis.

Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.

A man living with advanced liver cancer has seen his tumour shrink by over half as “exciting” new clinical trials are ...

Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today presented positive, final data from the ...

Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...

A groundbreaking cancer study led by Professor Tom Bird from the Cancer Research UK Scotland Institute has discovered a drug ...

A new study in the Journal of Interferon & Cytokine Research (JICR) showed that a specific retinoic acid-inducible gene I ...

Hepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates.

Luminescent gold nanoparticles (L-AuNPs) represent a novel class of luminescent nanomaterials that have attracted ...

IntroductionHepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates. It arises from ...